Department of Medicine, Division of Infectious Diseases and Immunology; Department of Medicine, Division of General Internal Medicine
Immunoprophylaxis and Therapy
To combat the threat of many emerging infectious diseases, DNA immunization offers a unique and powerful approach to the production of high-quality monoclonal antibodies (mAbs) against various pathogens. Compared with traditional protein-based immunization approaches, DNA immunization is efficient for testing novel immunogen designs, does not require the production or purification of proteins from a pathogen or the use of recombinant protein technology and is effective at generating mAbs against conformation-sensitive targets. Although significant progress in the use of DNA immunization to generate mAbs has been made over the last two decades, the literature does not contain an updated summary of this experience. The current review provides a comprehensive analysis of the literature, including our own work, describing the use of DNA immunization to produce highly functional mAbs, in particular, those against emerging infectious diseases. Critical factors such as immunogen design, delivery approach, immunization schedule, use of immune modulators and the role of final boost immunization are discussed in detail.
DOI of Published Version
Emerg Microbes Infect. 2016 Apr 6;5:e33. doi: 10.1038/emi.2016.27. Link to article on publisher's site
Emerging microbes and infections
Liu S, Wang S, Lu S. (2016). DNA immunization as a technology platform for monoclonal antibody induction. Open Access Publications by UMMS Authors. https://doi.org/10.1038/emi.2016.27. Retrieved from https://escholarship.umassmed.edu/oapubs/2864
Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.